yes.. good conversation ...
the most important takeaway for me is they would love to see value in bavi and the IP... but the market will determine that..
and if there is interest. it needs to be in stronger hands..
they will hire an IB to evaluate and hopefully sell to BP... if there is value there, they will try to get max.. they will be methodical.. lots to work out regarding sale and structure
stafford has been in biotech for twenty years, knows players and knows how to do deals...
i agreed with that plan because mgmt has no business running anymore trials because of the dilution and how could they compete with BP in getting patients... (and getting messed with again) and even if they were successful, the company has no credibility... the BOD is a major drag on the company...
on the IP side and from another source, confirmed that the msk comment on the cc call about car-t is true... what impact on value, who knows..
so putting the two calls together, imo there should be some level of interest but at what price... throw in patent exp issues etc.. lots to sort out but the tech needs to be in better hands... just wonder if wolchok could help with placement... and i'm sure stafford folks would explore that avenue
IMO we have a choice of proven operators that would do a much better job of creating value and aligning themselves with shareholders.. stafford was paid $40k in cash at xencor and brings value to the party vs the $300k paid to PPHM lampreys that offer no value and hurt the company in the institutional markets...
The BOD imo is really hurting MC.... and the company keeps raising money to pay BOD fees... If the BOD stepped down tomorrow, we would get a big jump in MC imo...
one more thing... the gravy train is over...
